H. Hatch

发表

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo

P. Majumder, Hiroshi Sootome, H. Hirai, 2010, Molecular Cancer Therapeutics.

Suppression of E-cadherin function drives the early stages of Ras-induced squamous cell carcinoma through up-regulation of FAK and Src

J. Garlick, A. Sowalsky, H. Hatch, 2011, The Journal of investigative dermatology.

Casein zymography of calpains using a 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid-imidazole buffer.

H. Hatch, D. E. Croall, K. Moffett, 2002, Analytical biochemistry.

Abstract #1751: MK-8033, a selective c-Met / Ron inhibitor, suppresses tumor cell growth in vitro and in vivo

P. Majumder, W. Lu, K. Kunii, 2009 .

Discovery of a 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancer.

K. Kunii, M. Altman, A. Szewczak, 2011, Journal of medicinal chemistry.

FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival.

Cem Elbi, K. Kunii, A. Di Bacco, 2008, Cancer research.

Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival.

N. Kohl, J. Gibbs, H. Hatch, 2007, Cancer research.

MCL1 and BCL-xL Levels in Solid Tumors Are Predictive of Dinaciclib-Induced Apoptosis

H. Hirsch, M. Ayers, A. Loboda, 2014, PloS one.

MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.

C. Paweletz, K. Kunii, I. Kariv, 2010, Cancer research.

FGFR 2-Amplified Gastric Cancer Cell Lines Require FGFR 2 and Erbb 3 Signaling for Growth and Survival

K. Kunii, M. Yashiro, H. Hatch, 2008 .

Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met.

Wei Lu, Michael D Altman, Craig Rosenstein, 2013, Journal of medicinal chemistry.

Discovery of a Novel cGAMP Competitive Ligand of the Inactive Form of STING.

M. Altman, H. Hatch, B. Pan, 2018, ACS medicinal chemistry letters.

Abstract #3714: In vitro and in vivo antitumor activities of MK-2206, a new allosteric Akt inhibitor

P. Majumder, K. Leander, H. Hatch, 2009 .

MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.

C. Paweletz, K. Kunii, I. Kariv, 2010, Cancer research.